Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib. View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04-05

AUTHORS

Kazuo Tamura, Toshihiro Nukiwa, Akihiko Gemma, Nobuyuki Yamamoto, Masaya Mizushima, Kaori Ochai, Rie Ikeda, Hisaya Azuma, Yoichi Nakanishi

ABSTRACT

BACKGROUND: This prospective, post-marketing observational study in Japanese patients aimed to evaluate the safety and effectiveness of daily afatinib use in general practice. METHODS: This non-interventional study (NCT02131259) enrolled treatment-naïve and pre-treated patients with inoperable/recurrent EGFR mutation-positive NSCLC, eligible for afatinib treatment as per the afatinib label in Japan. Patients received afatinib at the approved dose (20, 30, 40, or 50 mg/day; physician decision), and were observed following treatment initiation for 52 weeks or until premature discontinuation. Primary endpoint was the incidence of adverse drug reactions (ADRs). Secondary endpoints included ADRs of special interest, and objective response rate (ORR). Post hoc Cox multivariate analyses were used to assess prognostic factors associated with the incidence of ADRs. RESULTS: 1602 patients, at 374 sites (April 2014-March 2015), were included in the analysis; 307 (19%) were aged ≥ 75 years. The most frequently reported ADRs (all/grade 3-4) were diarrhea (78%/15%), rash/acne (59%/6%), stomatitis (31%/4%), and nail effects (38%/4%). Serious ADRs resulting in death occurred in 18 patients (1%). 762 patients (48%) had ≥ 1 afatinib dose reduction and 366 (23%) discontinued due to ADRs; the most common reason for both was diarrhea (8.2% and 6.7%, respectively). ORR was 40.1%. CONCLUSIONS: Real-world treatment of 1602 Japanese patients with afatinib was associated with a predictable ADR profile. Afatinib showed effectiveness in inoperable/recurrent EGFR mutation-positive NSCLC, especially as first-line treatment. As with other EGFR TKIs, prompt management of adverse events is needed in the Japanese population, to reduce serious events and outcomes, including interstitial lung disease. More... »

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10147-019-01439-5

DOI

http://dx.doi.org/10.1007/s10147-019-01439-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113261832

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30953238


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Fukuoka University", 
          "id": "https://www.grid.ac/institutes/grid.411497.e", 
          "name": [
            "General Medical Research Center, School of Medicine, Fukuoka University, Fukuoka, Japan. ktamura@fukuoka-u.ac.jp."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tamura", 
        "givenName": "Kazuo", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tohoku University", 
          "id": "https://www.grid.ac/institutes/grid.69566.3a", 
          "name": [
            "Tohoku University, Miyagi, Japan."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nukiwa", 
        "givenName": "Toshihiro", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nippon Medical School", 
          "id": "https://www.grid.ac/institutes/grid.410821.e", 
          "name": [
            "Nippon Medical School, Tokyo, Japan."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gemma", 
        "givenName": "Akihiko", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wakayama Medical University", 
          "id": "https://www.grid.ac/institutes/grid.412857.d", 
          "name": [
            "Division of Pulmonology and Medical Oncology, Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamamoto", 
        "givenName": "Nobuyuki", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Boehringer Ingelheim (Japan)", 
          "id": "https://www.grid.ac/institutes/grid.459839.a", 
          "name": [
            "Speciality Care Medicine, Medical Division, Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mizushima", 
        "givenName": "Masaya", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "PMS Division, Statistics Analysis Department 2, EPS Corporation, Tokyo, Japan."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ochai", 
        "givenName": "Kaori", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Boehringer Ingelheim (Japan)", 
          "id": "https://www.grid.ac/institutes/grid.459839.a", 
          "name": [
            "Post Marketing Surveillance Group, Pharmacovigilance, Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ikeda", 
        "givenName": "Rie", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Boehringer Ingelheim (Japan)", 
          "id": "https://www.grid.ac/institutes/grid.459839.a", 
          "name": [
            "Speciality Care Medicine, Medical Division, Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Azuma", 
        "givenName": "Hisaya", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kyushu University", 
          "id": "https://www.grid.ac/institutes/grid.177174.3", 
          "name": [
            "Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyusyu University, Fukuoka, Japan."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakanishi", 
        "givenName": "Yoichi", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1093/jjco/hyt049", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002292572"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(13)70604-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009186895"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.04.9866", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009790532"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/jpet.112.197756", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017522498"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.45.0981", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021155467"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.45.0981", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021155467"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.44.2806", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022055849"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.44.2806", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022055849"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18632/oncotarget.12587", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023416114"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.lungcan.2013.11.016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029476681"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0b013e3181ca12e0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030088864"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/cas.12723", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030903291"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/cas.12723", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030903291"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)71173-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036794393"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-014-2403-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039822128", 
          "https://doi.org/10.1007/s00280-014-2403-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0b013e3182598abb", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051420858"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdw322", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059394827"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdw322", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059394827"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.cllc.2018.03.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101555690"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.cllc.2018.03.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101555690"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.lungcan.2018.10.028", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107983995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.lungcan.2018.10.028", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107983995"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04-05", 
    "datePublishedReg": "2019-04-05", 
    "description": "BACKGROUND: This prospective, post-marketing observational study in Japanese patients aimed to evaluate the safety and effectiveness of daily afatinib use in general practice.\nMETHODS: This non-interventional study (NCT02131259) enrolled treatment-na\u00efve and pre-treated patients with inoperable/recurrent EGFR mutation-positive NSCLC, eligible for afatinib treatment as per the afatinib label in Japan. Patients received afatinib at the approved dose (20, 30, 40, or 50\u00a0mg/day; physician decision), and were observed following treatment initiation for 52\u00a0weeks or until premature discontinuation. Primary endpoint was the incidence of adverse drug reactions (ADRs). Secondary endpoints included ADRs of special interest, and objective response rate (ORR). Post hoc Cox multivariate analyses were used to assess prognostic factors associated with the incidence of ADRs.\nRESULTS: 1602 patients, at 374 sites (April 2014-March 2015), were included in the analysis; 307 (19%) were aged\u2009\u2265\u200975\u00a0years. The most frequently reported ADRs (all/grade 3-4) were diarrhea (78%/15%), rash/acne (59%/6%), stomatitis (31%/4%), and nail effects (38%/4%). Serious ADRs resulting in death occurred in 18 patients (1%). 762 patients (48%) had\u2009\u2265\u20091 afatinib dose reduction and 366 (23%) discontinued due to ADRs; the most common reason for both was diarrhea (8.2% and 6.7%, respectively). ORR was 40.1%.\nCONCLUSIONS: Real-world treatment of 1602 Japanese patients with afatinib was associated with a predictable ADR profile. Afatinib showed effectiveness in inoperable/recurrent EGFR mutation-positive NSCLC, especially as first-line treatment. As with other EGFR TKIs, prompt management of adverse events is needed in the Japanese population, to reduce serious events and outcomes, including interstitial lung disease.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10147-019-01439-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1312225", 
        "issn": [
          "1341-9625", 
          "1437-7772"
        ], 
        "name": "International Journal of Clinical Oncology", 
        "type": "Periodical"
      }
    ], 
    "name": "Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib.", 
    "productId": [
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30953238"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9616295"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10147-019-01439-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113261832"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10147-019-01439-5", 
      "https://app.dimensions.ai/details/publication/pub.1113261832"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T14:16", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000372_0000000372/records_117088_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s10147-019-01439-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10147-019-01439-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10147-019-01439-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10147-019-01439-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10147-019-01439-5'


 

This table displays all metadata directly associated to this object as RDF triples.

172 TRIPLES      20 PREDICATES      40 URIs      16 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10147-019-01439-5 schema:about anzsrc-for:11
2 anzsrc-for:1117
3 schema:author Ne997e873b079472a99f02cf940aab8a3
4 schema:citation sg:pub.10.1007/s00280-014-2403-2
5 https://doi.org/10.1016/j.cllc.2018.03.009
6 https://doi.org/10.1016/j.lungcan.2013.11.016
7 https://doi.org/10.1016/j.lungcan.2018.10.028
8 https://doi.org/10.1016/s1470-2045(13)70604-1
9 https://doi.org/10.1016/s1470-2045(14)71173-8
10 https://doi.org/10.1093/annonc/mdw322
11 https://doi.org/10.1093/jjco/hyt049
12 https://doi.org/10.1097/jto.0b013e3181ca12e0
13 https://doi.org/10.1097/jto.0b013e3182598abb
14 https://doi.org/10.1111/cas.12723
15 https://doi.org/10.1124/jpet.112.197756
16 https://doi.org/10.1200/jco.2005.04.9866
17 https://doi.org/10.1200/jco.2012.44.2806
18 https://doi.org/10.1200/jco.2012.45.0981
19 https://doi.org/10.18632/oncotarget.12587
20 schema:datePublished 2019-04-05
21 schema:datePublishedReg 2019-04-05
22 schema:description BACKGROUND: This prospective, post-marketing observational study in Japanese patients aimed to evaluate the safety and effectiveness of daily afatinib use in general practice. METHODS: This non-interventional study (NCT02131259) enrolled treatment-naïve and pre-treated patients with inoperable/recurrent EGFR mutation-positive NSCLC, eligible for afatinib treatment as per the afatinib label in Japan. Patients received afatinib at the approved dose (20, 30, 40, or 50 mg/day; physician decision), and were observed following treatment initiation for 52 weeks or until premature discontinuation. Primary endpoint was the incidence of adverse drug reactions (ADRs). Secondary endpoints included ADRs of special interest, and objective response rate (ORR). Post hoc Cox multivariate analyses were used to assess prognostic factors associated with the incidence of ADRs. RESULTS: 1602 patients, at 374 sites (April 2014-March 2015), were included in the analysis; 307 (19%) were aged ≥ 75 years. The most frequently reported ADRs (all/grade 3-4) were diarrhea (78%/15%), rash/acne (59%/6%), stomatitis (31%/4%), and nail effects (38%/4%). Serious ADRs resulting in death occurred in 18 patients (1%). 762 patients (48%) had ≥ 1 afatinib dose reduction and 366 (23%) discontinued due to ADRs; the most common reason for both was diarrhea (8.2% and 6.7%, respectively). ORR was 40.1%. CONCLUSIONS: Real-world treatment of 1602 Japanese patients with afatinib was associated with a predictable ADR profile. Afatinib showed effectiveness in inoperable/recurrent EGFR mutation-positive NSCLC, especially as first-line treatment. As with other EGFR TKIs, prompt management of adverse events is needed in the Japanese population, to reduce serious events and outcomes, including interstitial lung disease.
23 schema:genre research_article
24 schema:inLanguage en
25 schema:isAccessibleForFree false
26 schema:isPartOf sg:journal.1312225
27 schema:name Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib.
28 schema:productId N1e4371fc6b694907a13ecabe0654e31f
29 N4e6be241049749628bb1ddf2a9468ac5
30 N9fd3b9b293874107b4c51eb88fab6bda
31 Ne62cac84a9154047be8aab35421ae10c
32 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113261832
33 https://doi.org/10.1007/s10147-019-01439-5
34 schema:sdDatePublished 2019-04-11T14:16
35 schema:sdLicense https://scigraph.springernature.com/explorer/license/
36 schema:sdPublisher N93116bbe716d4bc08ceb4216e83cfab2
37 schema:url http://link.springer.com/10.1007/s10147-019-01439-5
38 sgo:license sg:explorer/license/
39 sgo:sdDataset articles
40 rdf:type schema:ScholarlyArticle
41 N1554853d2a7f47b2ab7578d2021ec2ce schema:name PMS Division, Statistics Analysis Department 2, EPS Corporation, Tokyo, Japan.
42 rdf:type schema:Organization
43 N1e4371fc6b694907a13ecabe0654e31f schema:name dimensions_id
44 schema:value pub.1113261832
45 rdf:type schema:PropertyValue
46 N2d99ec8b0b9f48f6929205197a3c14d1 rdf:first N383a02b952c444029a958a5daa6826d2
47 rdf:rest N3eef7e74459141658e26fed5cc86faf9
48 N383a02b952c444029a958a5daa6826d2 schema:affiliation https://www.grid.ac/institutes/grid.412857.d
49 schema:familyName Yamamoto
50 schema:givenName Nobuyuki
51 rdf:type schema:Person
52 N3eef7e74459141658e26fed5cc86faf9 rdf:first Nc3d09838ff254aac8d970d5c4672b896
53 rdf:rest N95cbf21d9835410991cae98cf6b1136d
54 N4cc83590f71b40d6a2ed02992b0c95df schema:affiliation https://www.grid.ac/institutes/grid.459839.a
55 schema:familyName Azuma
56 schema:givenName Hisaya
57 rdf:type schema:Person
58 N4e6be241049749628bb1ddf2a9468ac5 schema:name pubmed_id
59 schema:value 30953238
60 rdf:type schema:PropertyValue
61 N658f7ca5f95443f98d5594d736353abf rdf:first N76d597493fa34541ba11d30beb39c7f1
62 rdf:rest rdf:nil
63 N6f11f3c89e64467f8e8e6406d26f4b1e rdf:first N4cc83590f71b40d6a2ed02992b0c95df
64 rdf:rest N658f7ca5f95443f98d5594d736353abf
65 N76d597493fa34541ba11d30beb39c7f1 schema:affiliation https://www.grid.ac/institutes/grid.177174.3
66 schema:familyName Nakanishi
67 schema:givenName Yoichi
68 rdf:type schema:Person
69 N76f8f1f490d045078e593f1ca3069419 rdf:first Na94abf112a404018906d107a66ce45ef
70 rdf:rest N6f11f3c89e64467f8e8e6406d26f4b1e
71 N835b3f951d1a4bdc8ba7422bc82ac8fb schema:affiliation https://www.grid.ac/institutes/grid.411497.e
72 schema:familyName Tamura
73 schema:givenName Kazuo
74 rdf:type schema:Person
75 N87d0e8929f4e4b379fc9ec81d19264d7 schema:affiliation https://www.grid.ac/institutes/grid.410821.e
76 schema:familyName Gemma
77 schema:givenName Akihiko
78 rdf:type schema:Person
79 N93116bbe716d4bc08ceb4216e83cfab2 schema:name Springer Nature - SN SciGraph project
80 rdf:type schema:Organization
81 N95cbf21d9835410991cae98cf6b1136d rdf:first Ndad965309ebc4e299119d5b623cb9191
82 rdf:rest N76f8f1f490d045078e593f1ca3069419
83 N9d1fdd2ef28b4a1b9997081d8ef7cb34 schema:affiliation https://www.grid.ac/institutes/grid.69566.3a
84 schema:familyName Nukiwa
85 schema:givenName Toshihiro
86 rdf:type schema:Person
87 N9fd3b9b293874107b4c51eb88fab6bda schema:name nlm_unique_id
88 schema:value 9616295
89 rdf:type schema:PropertyValue
90 Na94abf112a404018906d107a66ce45ef schema:affiliation https://www.grid.ac/institutes/grid.459839.a
91 schema:familyName Ikeda
92 schema:givenName Rie
93 rdf:type schema:Person
94 Nc3d09838ff254aac8d970d5c4672b896 schema:affiliation https://www.grid.ac/institutes/grid.459839.a
95 schema:familyName Mizushima
96 schema:givenName Masaya
97 rdf:type schema:Person
98 Ncd8a075380a44f06b7d99d4847b6eebd rdf:first N9d1fdd2ef28b4a1b9997081d8ef7cb34
99 rdf:rest Nfffb526079f34772a7424e3581eab31a
100 Ndad965309ebc4e299119d5b623cb9191 schema:affiliation N1554853d2a7f47b2ab7578d2021ec2ce
101 schema:familyName Ochai
102 schema:givenName Kaori
103 rdf:type schema:Person
104 Ne62cac84a9154047be8aab35421ae10c schema:name doi
105 schema:value 10.1007/s10147-019-01439-5
106 rdf:type schema:PropertyValue
107 Ne997e873b079472a99f02cf940aab8a3 rdf:first N835b3f951d1a4bdc8ba7422bc82ac8fb
108 rdf:rest Ncd8a075380a44f06b7d99d4847b6eebd
109 Nfffb526079f34772a7424e3581eab31a rdf:first N87d0e8929f4e4b379fc9ec81d19264d7
110 rdf:rest N2d99ec8b0b9f48f6929205197a3c14d1
111 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
112 schema:name Medical and Health Sciences
113 rdf:type schema:DefinedTerm
114 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
115 schema:name Public Health and Health Services
116 rdf:type schema:DefinedTerm
117 sg:journal.1312225 schema:issn 1341-9625
118 1437-7772
119 schema:name International Journal of Clinical Oncology
120 rdf:type schema:Periodical
121 sg:pub.10.1007/s00280-014-2403-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039822128
122 https://doi.org/10.1007/s00280-014-2403-2
123 rdf:type schema:CreativeWork
124 https://doi.org/10.1016/j.cllc.2018.03.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101555690
125 rdf:type schema:CreativeWork
126 https://doi.org/10.1016/j.lungcan.2013.11.016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029476681
127 rdf:type schema:CreativeWork
128 https://doi.org/10.1016/j.lungcan.2018.10.028 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107983995
129 rdf:type schema:CreativeWork
130 https://doi.org/10.1016/s1470-2045(13)70604-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009186895
131 rdf:type schema:CreativeWork
132 https://doi.org/10.1016/s1470-2045(14)71173-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036794393
133 rdf:type schema:CreativeWork
134 https://doi.org/10.1093/annonc/mdw322 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059394827
135 rdf:type schema:CreativeWork
136 https://doi.org/10.1093/jjco/hyt049 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002292572
137 rdf:type schema:CreativeWork
138 https://doi.org/10.1097/jto.0b013e3181ca12e0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030088864
139 rdf:type schema:CreativeWork
140 https://doi.org/10.1097/jto.0b013e3182598abb schema:sameAs https://app.dimensions.ai/details/publication/pub.1051420858
141 rdf:type schema:CreativeWork
142 https://doi.org/10.1111/cas.12723 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030903291
143 rdf:type schema:CreativeWork
144 https://doi.org/10.1124/jpet.112.197756 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017522498
145 rdf:type schema:CreativeWork
146 https://doi.org/10.1200/jco.2005.04.9866 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009790532
147 rdf:type schema:CreativeWork
148 https://doi.org/10.1200/jco.2012.44.2806 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022055849
149 rdf:type schema:CreativeWork
150 https://doi.org/10.1200/jco.2012.45.0981 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021155467
151 rdf:type schema:CreativeWork
152 https://doi.org/10.18632/oncotarget.12587 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023416114
153 rdf:type schema:CreativeWork
154 https://www.grid.ac/institutes/grid.177174.3 schema:alternateName Kyushu University
155 schema:name Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyusyu University, Fukuoka, Japan.
156 rdf:type schema:Organization
157 https://www.grid.ac/institutes/grid.410821.e schema:alternateName Nippon Medical School
158 schema:name Nippon Medical School, Tokyo, Japan.
159 rdf:type schema:Organization
160 https://www.grid.ac/institutes/grid.411497.e schema:alternateName Fukuoka University
161 schema:name General Medical Research Center, School of Medicine, Fukuoka University, Fukuoka, Japan. ktamura@fukuoka-u.ac.jp.
162 rdf:type schema:Organization
163 https://www.grid.ac/institutes/grid.412857.d schema:alternateName Wakayama Medical University
164 schema:name Division of Pulmonology and Medical Oncology, Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
165 rdf:type schema:Organization
166 https://www.grid.ac/institutes/grid.459839.a schema:alternateName Boehringer Ingelheim (Japan)
167 schema:name Post Marketing Surveillance Group, Pharmacovigilance, Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan.
168 Speciality Care Medicine, Medical Division, Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan.
169 rdf:type schema:Organization
170 https://www.grid.ac/institutes/grid.69566.3a schema:alternateName Tohoku University
171 schema:name Tohoku University, Miyagi, Japan.
172 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...